No Data
No Data
$100 Invested In This Stock 15 Years Ago Would Be Worth $5,100 Today
Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 15 years by 17.42% on an annualized basis producing an average annual return of 29.68%. Currently, Regeneron
Regeneron Pharma Is Maintained at Neutral by Cantor Fitzgerald
Regeneron Pharma Is Maintained at Neutral by Cantor
HRMY or REGN: Which Is the Better Value Stock Right Now?
Cantor Fitzgerald Adjusts Price Target on Regeneron Pharmaceuticals to $1,000 From $925
Regeneron Pharmaceuticals (REGN) has an average outperform rating and price target range of $720 to $1,300, according to analysts polled by Capital IQ.Price: 1,069.52, Change: +5.92, Percent Change: +
Express News | Regeneron Pharmaceuticals Inc : Jefferies Raises Target Price to $1,235 From $1,135
Peering Into Regeneron Pharmaceuticals's Recent Short Interest
Regeneron Pharmaceuticals's (NYSE:REGN) short percent of float has risen 10.17% since its last report. The company recently reported that it has 2.04 million shares sold short, which is 1.95% of all
RDK79 : I recognized one word in that lead sentence:)))
But it sounds like good news!!!